1784.TWO Bionet
- Market cap
- TWD 2.38B
- P/E
- 40.6x
- P/B
- 2.02x
- ROE
- 5.2%
- Dividend yield
- 2.94%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 1784.TWO undervalued?
Graham number1784.TWO trades 91.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bionet fundamental analysis
No fundamental analysis for Bionet yet.
Bionet stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bionet
BIONET Corp. engages in cell therapy, regenerative medicine, medical big data, gene testing, and sales of biological and scientific information hardware and software business in Taiwan and internationally. The company offers stem cell banking services, such as stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and PBSC and immune cells, as well as skin care products. It also provides storage and application of hematopoietic stem ce…
Full company profileBionet financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bionet annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 697M | 771M | 776M | 807M | 921M | 980M | 1.13B | 1.22B | 1.24B | 1.31B |
| Gross Profit | 366M | 443M | 422M | 412M | 503M | 542M | 638M | 686M | 684M | 729M |
| Operating Income | -2.85M | 34.2M | 8.83M | 7.57M | 41.9M | 74.0M | 109M | 63.0M | -12.1M | 8.37M |
| EBITDA | 26.6M | 62.0M | 68.4M | 45.6M | 80.7M | 117M | 149M | 149M | 83.1M | 118M |
| Net Income | -6.27M | 24.2M | 6.80M | 12.7M | 26.6M | 38.0M | 78.4M | 83.7M | 51.4M | 64.3M |
| EPS | -0.13 | 0.50 | 0.14 | 0.27 | 0.56 | 0.80 | 1.66 | 1.65 | 1.02 | 1.29 |
| Balance Sheet | ||||||||||
| Total Assets | 1.82B | 1.78B | 1.76B | 1.73B | 1.78B | 1.84B | 2.35B | 3.16B | 3.08B | 3.08B |
| Total Liabilities | 453M | 443M | 454M | 445M | 468M | 514M | 626M | 760M | 823M | 879M |
| Shareholders' Equity | 1.12B | 1.10B | 1.07B | 1.08B | 1.10B | 1.08B | 1.19B | 1.33B | 1.27B | 1.23B |
| Cash & Short-term Investments | 122M | 96.0M | 78.9M | 390M | 385M | 439M | 907M | 243M | 256M | 197M |
| Total Debt | - | - | - | 27.1M | 14.5M | 15.2M | 45.0M | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -24.9M | -13.0M | 2.67M | 73.7M | 13.9M | 94.7M | 153M | 176M | 148M | 110M |
| Capital Expenditure | 9.95M | 16.6M | 11.6M | 38.0M | 16.7M | 32.9M | 26.3M | 103M | 132M | 47.6M |
| Free Cash Flow | -35.9M | -29.8M | -14.5M | 35.6M | -2.79M | 61.7M | 127M | 73.0M | 15.9M | 62.5M |
| Ratios | ||||||||||
| ROE | -0.6% | 2.2% | 0.6% | 1.2% | 2.4% | 3.5% | 6.6% | 6.3% | 4.0% | 5.2% |
| ROA | -0.3% | 1.4% | 0.4% | 0.7% | 1.5% | 2.1% | 3.3% | 2.7% | 1.7% | 2.1% |
| Net Profit Margin | -0.9% | 3.1% | 0.9% | 1.6% | 2.9% | 3.9% | 7.0% | 6.8% | 4.2% | 4.9% |
| Debt to Equity | - | - | - | 0.03x | 0.01x | 0.01x | 0.04x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bionet dividends
- Dividend yield
- 2.94%
- Forward dividend
- 0.88 TWD
- Payout ratio
- 136.2%
- Ex-dividend date
- Oct 1, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 70.1M | 1.39 | 136.2% |
| 2024 | TWD 33.2M | 0.65 | 39.6% |
| 2023 | TWD 32.6M | 0.69 | 41.6% |
| 2022 | TWD 23.5M | 0.50 | 61.9% |
| 2021 | TWD 8.77M | 0.18 | 32.9% |
| 2020 | TWD 18.3M | 0.39 | 143.9% |
| 2019 | TWD 13.3M | 0.28 | 195.8% |
| 2018 | TWD 13.3M | 0.28 | 55.0% |
| 2017 | TWD 13.3M | 0.27 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1070.9238:1000 on Sep 19, 2024.
Who owns Bionet
- Insiders 17.58%
- Institutions 0.16%
- Public & others 82.26%
- Shares outstanding 52.0M
- Free float 39.4M
Bionet company profile
- Company name
- Bionet
- Ticker
- 1784.TWO
- ISIN
- TW0001784007
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- Xinhu 1st Road, Taipei, Taiwan, 114065
- Phone
- 886 2 2795 1777
- Website
- bionetcorp.com
About Bionet
BIONET Corp. engages in cell therapy, regenerative medicine, medical big data, gene testing, and sales of biological and scientific information hardware and software business in Taiwan and internationally. The company offers stem cell banking services, such as stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and PBSC and immune cells, as well as skin care products. It also provides storage and application of hematopoietic stem cells, analytical testing, clinical and preclinical research, commercialized cell-derived products, and Exosome, a cell-free therapy. The company was founded in 1989 and is based in Taipei City, Taiwan.
Bionet management
4- Mr. Qing Yuan KangGeneral Manager
- Peiyi LiuSenior Manager of Finance Department
- Qianyu LiuAccounting Supervisor
- Mei Hua LaiVice President of Administrative Office